更正：德克尔，S.E.；邓，L. 非小细胞肺癌中靶向KRAS突变的临床进展与挑战。2024年，，3885。
Correction: Dekker, S.E.; Deng, L. Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer. 2024, , 3885.
作者信息
Dekker Simone E, Deng Lei
机构信息
Division of Hematology and Oncology, Department of Medicine, School of Medicine, University of Washington, Seattle, WA 98195, USA.
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
出版信息
Cancers (Basel). 2024 Dec 31;17(1):98. doi: 10.3390/cancers17010098.
Abstract
In the original publication [...].
摘要
在原始出版物中[...]。
相似文献
1
Correction: Dekker, S.E.; Deng, L. Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer. 2024, , 3885.更正：德克尔，S.E.；邓，L. 非小细胞肺癌中靶向KRAS突变的临床进展与挑战。2024年，，3885。
Cancers (Basel). 2024 Dec 31;17(1):98. doi: 10.3390/cancers17010098.
2
Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer.非小细胞肺癌中靶向KRAS突变的临床进展与挑战
Cancers (Basel). 2024 Nov 20;16(22):3885. doi: 10.3390/cancers16223885.
3
-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges.- 突变型非小细胞肺癌：从过去的努力到未来的挑战。
Int J Mol Sci. 2022 Aug 20;23(16):9391. doi: 10.3390/ijms23169391.
4
Targeting the undruggable oncogenic KRAS: the dawn of hope.靶向不可成药的致癌 KRAS：希望的曙光。
JCI Insight. 2022 Jan 11;7(1):e153688. doi: 10.1172/jci.insight.153688.
5
High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.高分辨率熔解分析用于临床样本中突变的快速灵敏检测：非小细胞肺癌中的KRAS第12和13密码子突变
BMC Cancer. 2006 Dec 21;6:295. doi: 10.1186/1471-2407-6-295.
6
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS-mutated non-small-cell lung cancer.解析 KRAS 突变型非小细胞肺癌的临床病理、基因组和免疫表型相关性。
Ann Oncol. 2022 Oct;33(10):1029-1040. doi: 10.1016/j.annonc.2022.07.005. Epub 2022 Jul 22.
7
Clinical characteristics, outcomes and prognostic factors in KRAS mutant lung cancers: experience from a tertiary care cancer center in India.KRAS 突变型肺癌的临床特征、结局及预后因素：来自印度一家三级癌症中心的经验
Ecancermedicalscience. 2024 Feb 22;18:1674. doi: 10.3332/ecancer.2024.1674. eCollection 2024.
8
KRAS-targeted therapy in the treatment of non-small cell lung cancer.KRAS 靶向治疗在非小细胞肺癌治疗中的应用。
J Oncol Pharm Pract. 2023 Mar;29(2):422-430. doi: 10.1177/10781552221118848. Epub 2022 Aug 8.
9
CRISPR and KRAS: a match yet to be made.CRISPR 与 KRAS：尚未匹配的一对。
J Biomed Sci. 2021 Nov 15;28(1):77. doi: 10.1186/s12929-021-00772-0.
10
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.K-Ras 突变型非小细胞肺癌的分子生物学与治疗前景
Cancers (Basel). 2022 Aug 24;14(17):4103. doi: 10.3390/cancers14174103.
本文引用的文献
1
Clinical Advances and Challenges in Targeting KRAS Mutations in Non-Small Cell Lung Cancer.非小细胞肺癌中靶向KRAS突变的临床进展与挑战
Cancers (Basel). 2024 Nov 20;16(22):3885. doi: 10.3390/cancers16223885.
Zotero 插件